Twist Bioscience (TWST)
NASDAQ:TWST
Top Page
Twist Bioscience
(NASDAQ:TWST)
Select Model
Select Model
Rating:55Neutral
Price Target:
$46.00
▲(6.33% Upside)
Action:ReiteratedDate:02/19/26
The score is held back primarily by still-negative cash flow and ongoing losses despite improving margins and a reasonable balance sheet. Offsetting this are strong technical momentum and a constructive earnings outlook with raised FY2026 guidance and a stated path to adjusted EBITDA breakeven, while valuation remains challenging given the negative earnings profile.
Positive Factors
Consistent multi-year revenue growth
Sustained top-line growth and a multi-year 24% CAGR provide durable validation of market demand and product-market fit. Consistent quarterly expansion supports scale benefits, stronger customer relationships, and a base for continued investment in automation and R&D over the next several quarters.
Negative Factors
Persistent negative operating and free cash flow
Continued cash burn means the business remains dependent on existing cash or external financing until operating cash flow turns positive. That constrains strategic flexibility and raises dilution or funding risk if revenue or margin progress slows before the targeted breakeven.
Read all positive and negative factors
Positive Factors
Negative Factors
Consistent multi-year revenue growth
Sustained top-line growth and a multi-year 24% CAGR provide durable validation of market demand and product-market fit. Consistent quarterly expansion supports scale benefits, stronger customer relationships, and a base for continued investment in automation and R&D over the next several quarters.
Read all positive factors
Twist Bioscience (TWST) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.65B
Dividend YieldN/A
Average Volume (3M)1.13M
Price to Earnings (P/E)―
Beta (1Y)2.01
Revenue Growth20.32%
EPS Growth63.81%
CountryUS
Employees923
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-0.50
Shares Outstanding61,311,703
10 Day Avg. Volume1,193,492
30 Day Avg. Volume1,131,290
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)3.56
Price to Sales (P/S)4.47
P/FCF Ratio-22.25
Enterprise Value/Market Cap1.11
Enterprise Value/Revenue7.53
Enterprise Value/Gross Profit14.59
Enterprise Value/Ebitda-57.64
Forecast
1Y Price Target
$53.00Price Target Upside22.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.81
Revenue Forecast (FY)$438.81M
Twist Bioscience Business Overview & Revenue Model
Company Description
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic D...
How the Company Makes Money
Twist Bioscience makes money primarily by selling synthetic DNA products and related services to life-science and industrial customers. Key revenue streams include: (1) Sales of synthetic DNA products, such as genes/gene fragments and clonal genes...
Twist Bioscience Earnings Call Summary
Earnings Call Date:Feb 02, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Apr 30, 2026
Earnings Call Sentiment Positive
The call emphasized continued, broad-based revenue growth (Q1 revenue +17% YoY), margin expansion (gross margin 52%, +~4 pts YoY), accelerating demand from AI-enabled discovery (notably 27% growth in DNA synthesis & protein solutions and meaningful gene/data volumes), and raised fiscal 2026 guidance with a reiterated commitment to adjusted EBITDA breakeven. Headline negatives include a continuing adjusted EBITDA loss, increased operating spend to fund growth, some customer concentration in NGS (previous single-customer volatility), and near-term margin moderation from new product launches. On balance, management portrayed strong operational momentum and a clear path to profitability while intentionally investing to capture growth opportunities.Positive Updates
Consistent Revenue Growth and Multi-Year CAGR
Q1 revenue of $103.7M, up 17% year-over-year and ~5% sequentially. Management noted the twelfth consecutive quarter of revenue growth and a three-year revenue CAGR of 24%.
Negative Updates
Adjusted EBITDA Still Loss-Making
Despite improvement, adjusted EBITDA remained a loss of approximately $13.4M in Q1 and the company used $24.8M in net cash from operating activities in the quarter.
Read all updates
Q1-2026 Updates
Positive
Negative
Consistent Revenue Growth and Multi-Year CAGR
Q1 revenue of $103.7M, up 17% year-over-year and ~5% sequentially. Management noted the twelfth consecutive quarter of revenue growth and a three-year revenue CAGR of 24%.
Read all positive updates
Company Guidance
Twist guided fiscal 2026 revenue of $435–$440 million (≈16% growth at the midpoint) and reiterated its commitment to adjusted EBITDA breakeven in 2026 while targeting full‑year gross margin above 52%; the company also provided a quarterly revenue range of $107–$108 million (≈16% YoY at the midpoint). Management pointed to Q1 as the foundation for the guide — Q1 revenue $103.7M (+17% YoY, ~+5% sequential) with 52% gross margin (+~4 pts YoY), DNA synthesis & protein solutions $51.1M (+27% YoY), NGS ~$52.6M (NGS ex‑one large customer +18% YoY), 271,000 genes shipped and >50,000 genes manufactured for data characterization — and noted AI‑related orders of >$25M in FY2025. They said ~75–80% (74% in Q1) of incremental revenue should drop to gross margin, revealed a Q1 adjusted EBITDA loss of ~$13.4M (improved ~$2.8M YoY), net cash used in operations $24.8M, CapEx $10M, and cash, equivalents & short‑term investments of $197.9M, while signaling they have accelerated operating expense by about $10M per quarter to drive growth without jeopardizing FY2026 breakeven.Twist Bioscience Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
63
Positive
Cash Flow
38
Negative
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 391.56M | 376.57M | 312.97M | 245.11M | 203.56M | 132.33M |
| Gross Profit | 202.13M | 191.00M | 133.35M | 89.73M | 84.23M | 51.71M |
| EBITDA | -51.16M | -52.10M | -176.71M | -174.15M | -211.68M | -143.91M |
| Net Income | -76.58M | -77.67M | -208.73M | -204.62M | -217.86M | -152.10M |
Balance Sheet | ||||||
| Total Assets | 638.09M | 641.86M | 614.32M | 776.40M | 961.38M | 702.10M |
| Cash, Cash Equivalents and Short-Term Investments | 197.95M | 232.43M | 276.40M | 336.41M | 504.97M | 477.86M |
| Total Debt | 183.86M | 137.32M | 85.03M | 94.07M | 94.91M | 62.92M |
| Total Liabilities | 181.99M | 168.90M | 141.63M | 152.97M | 171.99M | 121.28M |
| Stockholders Equity | 456.10M | 472.96M | 472.69M | 623.43M | 789.38M | 580.82M |
Cash Flow | ||||||
| Free Cash Flow | -86.72M | -75.63M | -69.17M | -170.25M | -226.24M | -139.31M |
| Operating Cash Flow | -51.01M | -47.63M | -64.09M | -142.47M | -124.39M | -112.24M |
| Investing Cash Flow | -33.16M | -24.76M | -3.07M | 50.61M | -232.93M | 156.16M |
| Financing Cash Flow | 10.89M | 28.54M | 6.89M | 911.00K | 270.53M | 329.18M |
Twist Bioscience Technical Analysis
Negative
43.26
Price Trends
46.35
Negative
39.24
Positive
35.24
Positive
Market Momentum
-0.34
Positive
44.60
Neutral
35.77
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TWST, the sentiment is Negative. The current price of 43.26 is below the 20-day moving average (MA) of 45.80, below the 50-day MA of 46.35, and above the 200-day MA of 35.24, indicating a neutral trend. The MACD of -0.34 indicates Positive momentum. The RSI at 44.60 is Neutral, neither overbought nor oversold. The STOCH value of 35.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TWST.
Twist Bioscience Risk Analysis
Twist Bioscience disclosed 61 risk factors in its most recent earnings report. Twist Bioscience reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Twist Bioscience Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $841.48M | -47.01 | -6.47% | ― | 14.46% | ― | |
55 Neutral | $2.65B | ― | -16.58% | ― | 20.32% | 63.81% | |
54 Neutral | $1.92B | -7.70 | -17.11% | ― | 20.53% | 82.91% | |
52 Neutral | $934.65M | -2.79 | -12.64% | ― | 10.10% | -44.29% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $488.13M | -8.63 | -5.40% | ― | 13.60% | 74.64% | |
48 Neutral | $407.70M | -1.57 | -79.81% | ― | 0.21% | -233.51% |
* Healthcare Sector Average
TWST
Twist Bioscience
43.26
4.32
11.09%
MYGN
Myriad Genetics
4.36
-4.48
-50.68%
NEO
NeoGenomics
7.20
-2.15
-22.99%
CDNA
CareDx
16.43
-1.27
-7.18%
FLGT
Fulgent Genetics
15.63
-1.68
-9.71%
GRAL
GRAIL Inc
46.90
21.80
86.85%
Twist Bioscience Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Twist Bioscience Expands Invenra Stake Through Equity Transactions
Positive
Feb 17, 2026
On February 11, 2026, Twist Bioscience Corporation agreed to issue up to 632,328 shares of common stock as part of a series of transactions with Invenra Inc. and two of its investors, including up to 324,558 shares and $5 million in cash to Invenr...
Executive/Board ChangesShareholder Meetings
Twist Bioscience Shareholders Back Directors and Governance Items
Positive
Feb 6, 2026
At its 2026 Annual Meeting of Stockholders, Twist Bioscience Corporation reported that approximately 91.81% of eligible shares were represented in person or by proxy, reflecting strong shareholder engagement. Stockholders elected three Class II di...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.